Table 3. Prescribing of anticholinergic drugs and mirabegron for overactive bladder in patients with dementia and non-dementia controls, in the 3-16 year period before a diagnosis of dementia or index date.
| Anticholinergic drug | Patients (n=170 742) | Controls (n=804 385) | ||
|---|---|---|---|---|
| No (%) prescribed drug treatment | Cumulative use of drug treatment* (median (IQR)) |
No (%) prescribed drug treatment | Cumulative use of drug treatment* (median (IQR)) |
|
| Darifenacin | 66 (0.04) | 84 (28-308) | 266 (0.03) | 112 (28-392) |
| Fesoterodine fumarate | 528 (0.3) | 140 (46.5-560) | 2118 (0.3) | 112 (28-448) |
| Flavoxate hydrochloride | 493 (0.3) | 22.5 (21-84) | 2106 (0.3) | 22.5 (21-67.5) |
| Oxybutynin hydrochloride | 7952 (4.7) | 37.3 (14-186.7) | 33 579 (4.1) | 28.7 (10-136) |
| Propiverine hydrochloride | 468 (0.3) | 84 (28-492) | 1725 (0.2) | 56 (28-392) |
| Solifenacin succinate | 4778 (2.8) | 202 (58-812) | 19 058 (2.4) | 168 (56-666) |
| Tolterodine tartrate | 7060 (4.1) | 112 (28-588) | 28 180 (3.5) | 98 (28-476) |
| Trospium chloride | 1518 (0.9) | 90 (30-367.5) | 5802 (0.7) | 84 (30-282) |
| Mirabegron (non-anticholinergic drug) | 416 (0.2) | 150 (60-439) | 1410 (0.2) | 120 (30-343) |
*
Total (cumulative) standardised daily dose of prescribed drug treatment (standardised doses derived from World Health Organization's defined daily dose for different drug treatments).
IQR, interquartile range.